Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30085708 | 0.91 | HRH3 (0.37) | HRH3KCNH2HRH1FPR2KDM1A | |
| SCHEMBL30085724 | 0.91 | HRH3 (0.36) | HRH3FPR2KDM1ASIGMAR1 | |
| SCHEMBL30085768 | 0.87 | KDM4E (0.38) | HRH3KCNH2FPR2KDM1AKDM4E | |
| SCHEMBL29925527 | 0.85 | KDM1A (0.33) | HRH3KCNH2FPR2KDM1ALMNA | |
| SCHEMBL29924699 | 0.83 | FPR2 (0.34) | KCNH2HRH1FPR2KDM1AALDH1A1 | |
| SCHEMBL29924781 | 0.83 | FPR2 (0.34) | HRH3KCNH2FPR2KDM1A | |
| SCHEMBL29924650 | 0.79 | FPR2 (0.36) | HRH3FPR2KDM1AALDH1A1KMT2A | |
| SCHEMBL30085771 | 0.79 | KDM1A (0.38) | HRH3KCNH2HRH1FPR2KDM1A | |
| SCHEMBL29925063 | 0.79 | CD274 (0.37) | HRH3KCNH2HRH1FPR2KDM1A | |
| SCHEMBL29924716 | 0.77 | HRH3 (0.42) | HRH3HRH4KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HRH3 4838/4885KCNH2 4582/4885HRH1 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.